在接受重复手术的患者中与发作复发相关的因素:回顾性分析
Yue Hu1,2, Guoqiang Chen1, Yaoling Liu1,2
1Department of Neurosurgery, Aviation General Hospital, Beijing, China.
Neurological research
|April 28, 2025
概括
重复手术可能是耐药患者的安全选择. 虽然超过一半的人实现了无,但手术前MRI发现和EEG结果影响了结果,近三分之一的人出现并发症.
科学领域:
- 神经外科 神经外科
- 发病学 (Epileptology) 是一个专业的学科.
- 临床神经学 临床神经学
背景情况:
- 手术对于耐药性来说至关重要,旨在实现无发作.
- 一些患者需要重复干预,因为在最初的手术后持续的发作.
研究的目的:
- 评估重复手术的结果和安全性.
- 在接受重复手术的患者中确定有利结果的预测因素.
主要方法:
- 对43名接受重复手术的患者进行了回顾性观察性研究.
- 标准化的评估包括脑电图 (EEG),磁共振成像 (MRI),在某些情况下,正子发射断层扫描 (PET) 和侵入性监测.
主要成果:
- 53.5%的患者取得了良好的结果 (ILAE类1或2),平均随访时间为43.95个月.
- 手术前的MRI病变预测了更好的结果 (OR=0.049),而多焦脑电图放电预测了更差的结果 (OR=25.082).
- 30.2%的患者出现了手术并发症,最常见的是视野缺陷,轻度半和感染.
结论:
- 重复性手术对于最初手术后不完全没有发作的患者来说是一个安全和有选择的选择.
- 在重复手术的情况下,全面的手术前评估对于优化结果至关重要.
相关概念视频
Seizures: Classification
277
Epilepsy is primarily characterized by unpredictable seizures, either provoked by an identifiable factor, such as injury or illness, or unprovoked, occurring spontaneously without apparent cause.
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
277
Arteries of the Lower Limbs
162
Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
162
Electroconvulsive Therapy
16
Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early...
16
Antiepileptic Drugs: Glutamate Antagonists
242
Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
242
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
180
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
180
Antiepileptic Drugs: GABAergic Pathway Potentiators
256
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
256


